



# Certificate of analysis

SFC864-03-02

Operator: Jane Vowles

Date: 25/01/2017

Supervisor: Sally Cowley

Date: 25/02/2018

Signature:

*SACowley*


# Source of fibroblasts and reprogramming information

- SF864 from UOXF
- Reprogrammed at UOXF-S
- Reprogrammed on 28/09/2016 at passage 4/JV
- Cytotune v2 WP3 SOP10


# Viability post-thaw and Morphology according to SOP19 passage 10

- Cell count immediately post-thaw  $1.98 \times 10^6$
- Viability immediately post-thaw 88.35%
- Photo at 24h and day 3 post-thaw (scale bar =  $100\mu\text{m}$ ):


24h post-thaw 80% plated



Day3 post-thaw 20% plated



# Sendai Cytotune 2 clearance: according to WP3 SOP15 undetectable at passage 10



Product sizes: SeV 181bp; KOS 528bp; SeV-Klf 410bp; SeV-Myc 532bp; Actin 623bp

# Mycoplasma Test:

## According to MycoAlert Lonza LT07-318 undetectable at passage 10

Sample	Clone	Passage number	Initial	Reading 1	Reading 2	Ratio/Status
+ve control				2.441	133.2	<b>54.57</b>
-ve control				3.105	0.606	<b>0.20</b>
5	SFC864-03-02	p10	CB	1.269	0.899	<b>0.71</b>

Results mean


Ratio **0 - 0.999** negative for mycoplasma

Ratio **1 – 1.3** Borderline Result (retest required)


Ratio above **1.3** positive for mycoplasma

# Flow cytometric analysis according to WP3 SOP 20 and 21 passage p12

Tra-1-60:



NANOG:



# SNP analysis

according to WP3 SOP Preparation of DNA and RNA samples for Illumina arrays

- Passage 10
- Identity to parent fibroblasts confirmed
- Karyotype abnormalities: none detected
- For details and raw data see StemDB